Complementary non-sputum diagnostic testing using oral swabs and urine LAM testing for TB in people with HIV

Running title: Oral swabs & urine LAM for TB diagnosis

Adrienne E. Shapiro[1,2], Alaina M. Olson[3], Lara Kidoguchi[1], Xin Niu[4], Zinhle Ngcobo[5], Zanele P. Magcaba[5], Mduduzi W. Ngwane[5], Grant R. Whitman[3], Kris M. Weigel[3], Rachel C. Wood[3], Doug P.K. Wilson[5,6], Paul K. Drain[1,2], Gerard A. Cangelosi[1,3,4*]

[1]Department of Global Health, University of Washington, Seattle, WA, USA; [2]Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA; [3]Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA; [4]Department of Epidemiology, University of Washington, Seattle, WA, USA; [5]Umkhuseli Research and Innovation Management, Pietermaritzburg, South Africa; [6]University of KwaZulu-Natal, Pietermaritzburg, South Africa

*Corresponding author: Gerard Cangelosi, Dept. of Environmental and Occupational Health Sciences, Box 351618, University of Washington, Seattle, WA 98195. Email: gcang@uw.edu

Key words: tuberculosis, oral swabs, diagnostic, urine, non-sputum, lipoarabinomannan (LAM), OSA, tongue swabs.

Abstract

Testing for mycobacterial lipoarabinomannan (LAM) in urine is a practical but insensitive

alternative to sputum testing to diagnose tuberculosis (TB) in people with HIV (PWH). We

evaluated urine LAM testing conducted in parallel with tests for *Mycobacterium tuberculosis*

DNA in oral swabs. In a cohort of 131 South Africans (92% with HIV), combined urine LAM and

oral swab testing was significantly more sensitive than either sample tested alone (57% vs. 35%

and 39%, respectively), and 97% specific, compared to reference sputum testing (TB culture

and Xpert Ultra). Complementary non-sputum sample testing increased sensitivity of TB

diagnosis, without sacrificing specificity.

Background

Tuberculosis disease (TB), caused by *Mycobacterium tuberculosis* (MTB), remains a

major cause of illness and death in PWH [1]. The standard sample for TB diagnosis is sputum,

which can be difficult for PWH to produce and insensitive in some patients. The availability of

noninvasive alternatives to sputum testing would substantially improve TB care for PWH [2, 3].

Immunoassays for mycobacterial lipoarabinomannan (LAM) in urine are potential

alternatives to sputum testing. However, the single WHO-approved urine LAM test (by

Alere/Abbott) lacks sensitivity. Although next-generation urine LAM tests are in development or

evaluation, even best-performing tests of the LAM analyte alone may not be optimally sensitive

to detect TB disease in PWH [4, 5].

In search of an alternative non-sputum sample type, we and others have shown that

MTB DNA can be detected by oral swab analysis (OSA) [6-14]. In OSA, the dorsum of the

tongue is brushed with a sterile swab, and the collected material is tested for MTB DNA. This

non-invasive, non-sputum sample collection approach can be applied to any patient, in any

setting, including tertiary hospital, outpatient clinic, remote health point, or home and community

settings.

Despite their promise, to date neither OSA nor urine LAM testing has proven to be

sensitive enough to detect all TB in PWH. We hypothesize that sensitivity is limited for different

reasons in the two methods. For example, pulmonary disease may be required to deposit

enough MTB in the mouth for detection by OSA, whereas a very high total mycobacterial burden,

including extrapulmonary disease, may be required for transrenal passage of MTB glycolipids

into urine. Therefore, a parallel approach using both methods may detect more TB cases in

PWH than either method alone. The current study was conducted to assess the

complementarity of the two methods.

Methods

Participant enrollment: South African adults (age ≥16 years) with HIV (regardless of

symptoms), or adults with TB symptoms or a positive sputum Xpert Ultra TB test, were

consecutively enrolled into the prospective PROVE-TB cohort at Edendale Hospital and

affiliated clinics in Pietermaritzburg, South Africa between October 2019 and February 2021.

Persons who had received TB treatment for more than 24 hours were excluded. Clinical,

laboratory, and demographic data were collected from participants and clinical charts. Sputum,

urine, tongue swab, and blood samples were collected at bedside and transported to the on-site

laboratory for processing and analysis. Study data were collected and managed using REDCap

electronic data capture tools hosted at the Institute of Translational Health Sciences. All

participants provided written informed consent. This study was approved by the ethical

committees of the University of KwaZulu-Natal (BREC #BE475/18) and the University of

Washington.

Sample collection and analysis. Expectorated sputum samples were tested with Cepheid

GeneXpert MTB/RIF Ultra (Xpert Ultra) and mycobacterial culture (National Health Laboratory

System, South Africa). A TB case was defined as a participant with either a positive sputum

Xpert Ultra or a positive sputum TB culture result (reference testing). Spontaneously passed

urine samples were tested for the presence of LAM using the Alere DETERMINE LAM Ag

lateral-flow assay. A result of 1+ or higher according to the manufacturer's visual read-out card

was considered positive. Two tongue dorsum swabs (Copan FLOQSwabs) were collected into

separate tubes as described previously [7, 8]. Swabs in 0.5 mL TE buffer were stored frozen at -

80 °C and transported to the Cangelosi Lab for blinded analysis. Thawed samples were

manually processed (Qiagen), concentrated by ethanol precipitation, and tested by IS6110-

targeted qPCR. Swab analysis methods were as described previously [7, 8] with the following

modifications. Post-boil samples were eluted from the swab head then split, 250 µL reserve and

250 µL for immediate processing by volume-scaled-lysis (300 µL each of Qiagen Buffer AL and

100% ethanol). The qPCR protocol used New England BioLabs® Inc Luna® Universal Probe

qPCR Master Mix, and the ethanol-precipitated samples were rehydrated in 5 µL TE buffer prior

to master mix addition. Cq values were recorded and results were calculated using two Cq

thresholds (38 as described previously [7, 8], and a more stringent value of 32).

In addition, a subset of reserved or duplicate oral swab samples (N=18) were tested

using by either of two methods. In one method, previously boiled, reserved (200 µL) half

samples were thawed and received 2.2 mL TE buffer. The samples were shaken on a lab

vortexer (GENIE® SI-0236 Vortex-Genie 2 Mixer, 120V) on setting 10 for 10-15 seconds, then

allowed to sit at ambient temperature for 5 minutes and then shaken for an additional 10-15

seconds, before allowing them sit for additional 10 minutes at ambient temperature. The entire

recoverable sample volume was transferred into the sample reservoir of the Xpert Ultra

cartridge for analysis. Samples were recorded as positive for MTB if GeneXpert software

returned any positive result. Some samples were run by an alternative method that did not use

heat. These 0.5-mL samples were thawed at ambient temperature for 30 min, then

supplemented with 0.3 mL TE and 1.6 mL of Cepheid Sample Reagent (SR). The samples were

vortexed for 10-15 seconds, and incubated for 5 minutes before vortexing for an additional 10-

15 seconds. The samples were further incubated for additional 10 minutes before the entire

sample volume was transferred to the cartridges.

Sensitivities and specificities of index methods (swabs, urine LAM, and parallel testing)

were calculated relative to the reference method (positive sputum Xpert Ultra or positive sputum

culture).

Results

We enrolled 131 participants (45% female, median age 36 years) who provided all sample types for index and reference testing. 120 (92%) participants had HIV. 64 (49%) were TB cases by reference testing **(Figure 1)**.

Relative to the sputum reference standard, OSA using manual qPCR conducted on a single swab, with a Cq cutoff of 38, was significantly more sensitive than urine LAM (respectively, 42/64 [67%] vs. 22/63 [35%]). However, OSA was less specific than urine LAM (respectively, 52/67 [78%] vs. 67/67 [100%]). When a more stringent Cq cutoff of 32 was applied to define a positive OSA result, OSA and urine LAM performed similarly (respectively, 25/64 [39%] vs. 22/63 [35%] sensitive, and 65/67 [97%] vs. 67/67 [100%] specific) **(Table 1).**

When evaluating parallel (combination) non-sputum testing, a positive index test was defined as being either urine LAM-positive or OSA-positive. With parallel testing, sensitivity improved to 36/63 [57%], significantly better than urine LAM alone (p=0.006) or OSA alone (p=0.021). Of the 36 participants who were true positive by non-sputum methods, 11 were positive by both methods while 25 were positive by only one or the other (14 by OSA and 11 by urine LAM; **Figure 1**). Specificity of the combined method remained high at 65/67 (97%).

The manual qPCR method used in Table 1 performed well in past OSA studies [7, 8, 14] but is impractical for routine diagnostic use. Therefore, as a secondary analysis we used the semi-automated Cepheid GeneXpert MTB/RIF Ultra platform to test a subset of 18 frozen swab samples from the current study (11 true positives with strong qPCR signals by OSA, 5 true negatives by OSA, and the 2 false positives by OSA). Xpert Ultra detected 10 of 11 true positives by OSA (the 11th sample had an invalid Xpert Ultra result). It correctly excluded all 5 true negatives by OSA. It also correctly excluded the 2 false positives by OSA **(Table S1).**

Discussion

Many PWH struggle to produce sputum (sputum-scarce) and/or have low MTB cell

counts in sputum (paucibacillary) [2, 3]. This study tested the hypothesis that parallel testing of

two different non-sputum samples can deliver complementary, not redundant diagnostic

information, and thereby serve as an alternative to sputum testing for at least some patients.

Recent years have seen advancements in urine LAM testing for sputum-scarce or

paucibacillary patients. LAM is an MTB cell wall glycolipid that can pass transrenally into urine.

In some patients, most notably PWH with low CD4 counts, LAM is found in the urine in sufficient

quantities to enable rapid detection by using lateral flow tests such as the Alere Determine[TM] TB

LAM Ag. However, the sensitivity of urine LAM tests remains suboptimal [4, 5].

We hypothesized that OSA can improve TB diagnosis in paucibacillary and sputum-

scarce patients when used in combination with urine LAM testing. The physiological bases for

urine LAM testing (transrenal passage of a mycobacterial glycolipid) and OSA (deposition of

MTB cells and/or DNA on the tongue dorsum during cough, exhalation, or spontaneous sputum

production) are likely to differ from each other. Urine LAM may work best in cases that are at

least partially extrapulmonary, while OSA may be best in pulmonary TB. The strengths and

limitations of the two methods may therefore complement each other.

The results were consistent with this hypothesis. When the more stringent Cq cutoff of

32 was applied, a diagnostic criterion of positivity in either urine LAM or OSA was significantly

more sensitive than either method alone. Specificity was acceptable at 97% and was the

minimum of the individual test specificities, but not lower in combination.

This study focused on the biological question of complementarity. Limitations associated

with implementation were only partially addressed. While swab sample collection has minimal

resource requirements, the manual qPCR method for OSA requires laboratory facilities,

specialized equipment and skilled technical operators, so is not practical for routine clinical

laboratory use in its current form. However, analysis of a subset of 18 samples with the near

point-of-care Xpert Ultra platform suggested that similar results can be obtained with automated

tests (with the caveat that the true-positive samples within the subset were strongly positive by

manual qPCR). Therefore, this strategy can in theory be applied in any setting with access to

both Alere Determine[TM] TB LAM AG and Xpert Ultra. Other automated amplification platforms

intended for near-point-of-care or point-of-care use are also in development and have the

potential to be configured for TB OSA.

Another implementation concern is the requirement for two laboratory tests per patient.

In context, the same limitation often applies to the current sputum-dependent strategies

(paucibacillary and sputum-scarce patients often require multiple sampling and testing attempts

to confirm TB). Urine and tongue swabs are easier and safer to collect than sputum samples in

most settings. To conserve resources, the two specimens could be collected simultaneously

and then tested in a staged reflex algorithm. By design, oral swabs are easy and inexpensive to

collect from any patient, in any setting. Swabs can therefore be collected and stored

concurrently with the collection of all urine samples. If a patient's urine sample is positive for

LAM, then that is diagnostic for TB and a swab test is not needed. If the urine LAM test is

negative, then the swab can be tested to avoid having to recall the patient for sputum induction.

In conclusion, our results indicate that tongue swabs and urine can serve as

complementary non-sputum samples for improved diagnosis of TB in PWH. With further

optimization to improve sensitivity, this approach may be considered as a fully non-sputum

strategy for detecting TB in sputum-scarce patients.

179
180

Footnote page

Conflict of interest statement: The authors have no conflicts of interest to declare.

This work was supported by the Bill and Melinda Gates Foundation (#INV-004527, OPP

1213054) and by NIH (NIAID) grant # R01AI139254. REDCap at ITHS is supported by the

National Center For Advancing Translational Sciences of the National Institutes of Health under

Award Number UL1 TR002319. AES is supported by NIH (NIAID) K23A140918. We are grateful

to Cepheid, Inc., for providing research-use-only Xpert Ultra test kits, and to Copan Italia for

providing swabs.

This work was presented in part at virtual TB Science 2021, (Abstract #TBS-LB-2021-02134)

199   **Figure 1. Venn diagram showing overlap of the 2 non-sputum tests (tongue swab and urine**
200   **LAM) and the sputum TB reference (Xpert Ultra or TB culture).** The number of positive
201   participants falling within each category is shown (N=131 participants).
202   *One TB ref+/OSA- participant had an invalid LAM result.
203

221
222
223
224
225   **Table 1. Sensitivity and specificity of non-sputum tests alone or in combination, compared to**
226   **TB reference standard (sputum Xpert Ultra or sputum culture).**
227

	Sensitivity	Specificity
Tongue Swab (OSA) Cq<32	25/64 (39%)	65/67 (97%)
Tongue Swab (OSA) Cq<38	42/64 (67%)	52/67 (78%)
Urine LF-LAM	22/63 (35%)	67/67 (100%)
LAM or OSA*$_{Cq<32}$	36/63 (57%)	65/67 (97%)
LAM or OSA*$_{Cq<38}$	45/63 (71%)	52/67 (78%)

228   * OSA by manual qPCR using 2 thresholds of positivity: Cq<38 (liberal) and Cq<32 (stringent).
229

Literature cited

1. World Health Organization. Global Tuberculosis Report 2020.
2. UNITAID. Tuberculosis diagnostics technology and market landscape - 5th edition. World Health Organization. 2017.
3. Fauci, AS, Eisinger RW. Reimagining the Research Approach to Tuberculosis. Am J Trop Med Hyg. 2018;98(3):650-2.
4. Shah M, Hanrahan C, Wang ZY, Dendukuri N, Lawn SD, Denkinger CM, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults. Cochrane Database of Systematic Reviews. 2016;(5).
5. Broger T, Sossen B, du Toit E, Kerkhoff AD, Schutz C, Ivanova Reipold E, et al. Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. The Lancet Infectious Diseases. 2019;19(8):852-61.
6. LaCourse SM, Seko E, Wood R, Bundi W, Ouma GS, Agaya J, et al. Diagnostic performance of oral swabs for non-sputum based TB diagnosis in a TB/HIV endemic setting. PLoS One. 2022;17(1):e0262123. Epub 2022/01/14.
7. Wood RC, Andama A, Hermansky G, Burkot S, Asege L, Job M, et al. Characterization of oral swab samples for diagnosis of pulmonary tuberculosis. PLOS ONE. 2021;16(5):e0251422. doi: 10.1371/journal.pone.0251422.
8. Luabeya AK, Wood RC, Shenje J, Filander E, Ontong C, Mabwe S, et al. Noninvasive Detection of Tuberculosis by Oral Swab Analysis. Journal of Clinical Microbiology. 2019;57(3):e01847-18.
9. Wood RC, Luabeya AK, Weigel KM, Wilbur AK, Jones-Engel L, Hatherill M, et al. Detection of Mycobacterium tuberculosis DNA on the oral mucosa of tuberculosis patients. Scientific Reports. 2015;5:8668.
10. Nicol MP, Wood RC, Workman L, Prins M, Whitman C, Ghebrekristos Y, et al. Microbiological diagnosis of pulmonary tuberculosis in children by oral swab polymerase chain reaction. Scientific Reports. 2019;9(1):10789.
11. Valinetz ED, Cangelosi GA. A Look Inside: Oral Sampling for Detection of Non-Oral Infectious Diseases. Journal of Clinical Microbiology. 2021:JCM.02360-20.
12. Flores JA, Calderon R, Mesman AW, Soto M, Coit J, Aliaga J, et al. Detection of Mycobacterium Tuberculosis DNA in Buccal Swab Samples from Children in Lima, Peru. The Pediatric Infectious Disease Journal. 2020;39(11).
13. Mesman AW, Calderon R, Soto M, Coit J, Aliaga J, Mendoza M, et al. Mycobacterium tuberculosis detection from oral swabs with Xpert MTB/RIF ULTRA: a pilot study. BMC Res Notes. 2019;12(1):349-.
14. Song Y, Ma Y, Liu R, Shang Y, Ma L, Huo F, et al. Diagnostic Yield of Oral Swab Testing by TB-LAMP for Diagnosis of Pulmonary Tuberculosis. Infect Drug Resist. 2021;14:89-95.